{
    "root": "303a7f17-6fc3-c110-e063-6294a90a584c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Imatinib Mesylate",
    "value": "20250313",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 102",
            "code": "PNR0YF693Y"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 200",
            "code": "5XDI2TS1EZ"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "IMATINIB MESYLATE",
            "code": "8A1O1M485B"
        }
    ],
    "indications": "Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 )",
    "contraindications": "Adults with Ph+ CML CP ( 2.2 ):                                        400 mg/day Adults with Ph+ CML AP or BC ( 2.2 ):                             600 mg/day Pediatrics with Ph+ CML CP ( 2.3 ):                             340 mg/m 2 /day Adults with Ph+ ALL ( 2.4 ):                                                600 mg/day Pediatrics with Ph+ ALL ( 2.5 ):                                    340 mg/m 2 /day Adults with MDS/MPD ( 2.6 ):                                            400 mg/day Adults with ASM ( 2.7 ):                              100 mg/day or 400 mg/day Adults with HES/CEL ( 2.8 ):                      100 mg/day or 400 mg/day Adults with DFSP ( 2.9 ):                                                      800 mg/day Adults with metastatic and/or unresectable GIST ( 2.10 ):   400 mg/day Adjuvant treatment of adults with GIST ( 2.11 ):                 400 mg/day Patients with mild to moderate hepatic impairment ( 2.12 ): 400 mg/day Patients with severe hepatic impairment ( 2.12 ):                  300 mg/day All doses of imatinib mesylate tablets should be taken with a meal and a large glass of water. Doses of 400 mg or 600 mg should be administered once daily, whereas a dose of 800 mg should be administered as 400 mg twice a day. Imatinib mesylate tablets can be dissolved in water or apple juice for patients having difficulty swallowing. Daily dosing of 800 mg and above should be accomplished using the 400-mg tablet to reduce exposure to iron.",
    "warningsAndPrecautions": "Imatinib film-coated tablets are supplied as 100 mg and 400 mg tablets for oral administration. Each 100 mg tablet contains 119.5 mg of imatinib mesylate equivalent to 100 mg of imatinib free base. Each 400 mg tablet contains 478 mg of imatinib mesylate equivalent to 400 mg of imatinib free base.\n  \n                     \n                     Imatinib Mesylate Tablets, 100 mg are very dark yellow to brownish orange film-coated tablets, round, biconvex with bevelled edges, debossed with '100' on one side, and score on the other side.\n  \n                     \nNDC 68001-622-05             Bottles of 90                                                     \n  \n                     \n                     Imatinib Mesylate Tablets, 400 mg are very dark yellow to brownish orange film-coated tablets, ovaloid, biconvex with bevelled edges, debossed with '400' on one side and score on the other side.\n  \n                     \nNDC 68001-623-04             Bottles of 30                                                    \n  \n                     \n                     Storage and Handling\n                     \n                     \n                     Store at20 \n  oto 25 \n  oC (68 \n  oto 77 \n  oF) [see USP Controlled Room Temperature]. Protect from moisture.\n  \n                     \nDispense in a tight container, USP.\n  \n                     \nDo not crush imatinib mesylate tablets. Avoid direct contact of crushed tablets with the skin or mucous membranes. If such contact occurs, wash thoroughly as outlined in the references. Avoid exposure to crushed tablets.",
    "adverseReactions": "None."
}